The ESMO clinical practise guidelines for early breast cancer: diagnosis, treatment and follow-up: on the winding road to personalized medicine
Author:
Funder
National Breast Cancer Foundation of Australia
Novartis
Bristol Meyers Squibb
Merck
Roche-Genentech
Puma Biotechnology
Pfizer
Seattle Genetics
Merck and Roche-Genentech
Publisher
Elsevier BV
Subject
Oncology,Hematology
Link
http://academic.oup.com/annonc/advance-article-pdf/doi/10.1093/annonc/mdz201/29022318/mdz201.pdf
Reference15 articles.
1. Early breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up;Cardoso;Ann Oncol,2019
2. De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017;Curigliano;Ann Oncol,2017
3. Adjuvant chemotherapy guided by a 21-gene expression assay in breast cancer;Sparano;N Engl J Med,2018
4. 70-gene signature as an aid to treatment decisions in early-stage breast cancer;Cardoso;N Engl J Med,2016
5. Tumor-infiltrating lymphocytes and prognosis: a pooled individual patient analysis of early-stage triple-negative breast cancers;Loi;J Clin Oncol,2019
Cited by 17 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Impact of Imaging Biomarkers and AI on Breast Cancer Management: A Brief Review;Cancers;2023-10-30
2. Artificial intelligence‐powered spatial analysis of tumor‐infiltrating lymphocytes as a biomarker in locally advanced unresectable thymic epithelial neoplasm: A single‐center, retrospective, longitudinal cohort study;Thoracic Cancer;2023-09-07
3. Comprehensive evaluation of the relationship between biomarker profiles and neoadjuvant chemotherapy outcomes for breast cancer patients;2023-06-08
4. Development and validation of a radiopathomic model for predicting pathologic complete response to neoadjuvant chemotherapy in breast cancer patients;BMC Cancer;2023-05-12
5. HORMAD1 overexpression predicts response to anthracycline–cyclophosphamide and survival in triple‐negative breast cancers;Molecular Oncology;2023-03-23
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3